logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Kiniksa Pharmaceuticals, Ltd.

KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā€¦ read more

Healthcare

Biotechnology

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$37.38

Price

-5.20%

-$2.05

$39.43

Previous Close

$39.29

Open

Premium

52w Discount
Market Cap

$2.770b

Mid

Price/Earnings

747.6x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$529.332m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$4.790m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

$0.04

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$495.007m

$661.150m

Assets

$166.143m

Liabilities

$9.765m

Debt
Debt to Assets

1.5%

1.7x

Debt to EBITDA
Free Cash Flow

$66.491m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.